Filing provides achievements to date and adjustments to reduce the risk of fire ignitions caused by utility infrastructure
Grid upgrades will lead to reduction and frequency of Public Safety Power. | February 11, 2021
MedCity News
Bristol Myers lymphoma therapy acquired in Celgene deal wins FDA nod
After some setbacks and delays, the FDA approved Bristol Myers Squibb’s Breyanzi for certain lymphomas. It’s the fourth CAR T treatment to win the regulatory nod and the first under a new regenerative medicine designation.
Shares1
A Bristol Myers Squibb cancer immunotherapy that the pharmaceutical giant obtained via its Celgene acquisition was awarded FDA approval Friday, adding one more of this type of personalized medicine as a treatment option for certain forms of lymphoma.
The FDA approved the therapy, lisocabtagene maraleucel, as a treatment for adults who have certain types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL), whose cancer has not responded to or has relapsed after at least two other types of treatment. New York-based BMS will market the drug under the name Breyanzi.